Ulcerative Colitis - Pipeline Review, H2 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Ulcerative Colitis - Pipeline Review, H2 2019
Summary
latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2019, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 18, 49, 34, 1, 67 and 19 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2019, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 18, 49, 34, 1, 67 and 19 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Introduction
Ulcerative Colitis - Overview
Ulcerative Colitis - Therapeutics Development
Ulcerative Colitis - Therapeutics Assessment
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development for Ulcerative Colitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Ulcerative Colitis - Pipeline by 4D Pharma Plc, H2 2019
Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2019
Ulcerative Colitis - Pipeline by AbGenomics International Inc, H2 2019
Ulcerative Colitis - Pipeline by Abivax SA, H2 2019
Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H2 2019
Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2019
Ulcerative Colitis - Pipeline by Algernon Pharmaceuticals Inc, H2 2019
Ulcerative Colitis - Pipeline by Alivio Therapeutics Inc, H2 2019
Ulcerative Colitis - Pipeline by Allergan Plc, H2 2019
Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2019
Ulcerative Colitis - Pipeline by Alvotech ehf, H2 2019
Ulcerative Colitis - Pipeline by Am-Pharma BV, H2 2019
Ulcerative Colitis - Pipeline by Amgen Inc, H2 2019
Ulcerative Colitis - Pipeline by Antibe Therapeutics Inc, H2 2019
Ulcerative Colitis - Pipeline by Apidel SA, H2 2019
Ulcerative Colitis - Pipeline by Applied Molecular Transport LLC, H2 2019
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H2 2019
Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, H2 2019
Ulcerative Colitis - Pipeline by AsiaBiome, H2 2019
Ulcerative Colitis - Pipeline by Asta Pharmaceuticals Co Ltd, H2 2019
Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H2 2019
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2019
Ulcerative Colitis - Pipeline by Avexegen Therapeutics Inc, H2 2019
Ulcerative Colitis - Pipeline by Axim Biotechnologies Inc, H2 2019
Ulcerative Colitis - Pipeline by Bausch Health Companies Inc, H2 2019
Ulcerative Colitis - Pipeline by BioXpress Therapeutics SA, H2 2019
Ulcerative Colitis - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Ulcerative Colitis - Pipeline by Bridge Biotherapeutics Inc, H2 2019
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Ulcerative Colitis - Pipeline by Celgene Corp, H2 2019
Ulcerative Colitis - Pipeline by Cellix Bio Pvt Ltd, H2 2019
Ulcerative Colitis - Pipeline by Celltrion Inc, H2 2019
Ulcerative Colitis - Pipeline by Chain Biotechnology Ltd, H2 2019
Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H2 2019
Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2019
Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
Ulcerative Colitis - Pipeline by Circle33 LLC, H2 2019
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2019
Ulcerative Colitis - Pipeline by Cristcot HCA LLC, H2 2019
Ulcerative Colitis - Pipeline by CrystalGenomics Inc, H2 2019
List Of Figures
Number of Products under Development for Ulcerative Colitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
RELATED REPORTS
Ulcerative Colitis (UC) Market in China 2023
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the
View ReportGlobal Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)
Executive Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and
View ReportUlcerative Colitis (UC) Market in China 2023
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the
View ReportGlobal Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)
Executive Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
